Phyllis van der Ploeg
Overview
Explore the profile of Phyllis van der Ploeg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
45
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van der Ploeg P, Hendrikse C, Thijs A, Westgeest H, Smedts H, Caroline Vos M, et al.
Heliyon
. 2024 Jan;
10(1):e23170.
PMID: 38187310
Objective: Ovarian cancer is the fifth cause of cancer-related death among women. The benefit of targeted therapy for ovarian cancer patients is limited even if treatment is stratified by molecular...
2.
Hendrikse C, van der Ploeg P, van de Kruis N, Wilting J, Oosterkamp F, Theelen P, et al.
Cancer
. 2023 Mar;
129(9):1361-1371.
PMID: 36867576
Background: Advanced low-grade ovarian carcinoma (LGOC) is difficult to treat. In several studies, high estrogen receptor (ER) protein expression was observed in patients with LGOC, which suggests that antihormonal therapy...
3.
van de Kruis N, van der Ploeg P, Wilting J, Caroline Vos M, Thijs A, de Hullu J, et al.
Gynecol Oncol Rep
. 2022 Jul;
42:101035.
PMID: 35898197
Objective: Clinical efficacy of cytostatic anticancer agents can be determined with the progression-free survival (PFS) ratio. This outcome measure compares PFS achieved by a new treatment (PFS2) to the PFS...
4.
van der Ploeg P, Uittenboogaard A, Bosch S, van Diest P, Wesseling-Rozendaal Y, van de Stolpe A, et al.
Gynecol Oncol
. 2022 Feb;
165(1):114-120.
PMID: 35123772
Objective: To determine the activity of key signal transduction pathways in serous tubal intraepithelial carcinoma (STIC) and concurrent high-grade serous carcinoma (HGSC) and compare this to pathway activity in normal...
5.
van der Ploeg P, Uittenboogaard A, Bucks K, Lentjes-Beer M, Bosch S, van Rumste M, et al.
Acta Obstet Gynecol Scand
. 2021 Dec;
101(2):256-264.
PMID: 34927235
Introduction: The local environment of the fallopian tube represents the optimal conditions for reproductive processes. To maintain tissue homeostasis, signal transduction pathways are thought to play a pivotal role. Enhancing...
6.
van Lieshout L, van der Ploeg P, Wesseling-Rozendaal Y, van de Stolpe A, Bosch S, Lentjes-Beer M, et al.
Cancers (Basel)
. 2021 Oct;
13(20).
PMID: 34680250
High-grade serous ovarian carcinoma (HGSC), the most common subtype of ovarian cancer, has a high mortality rate. Although there are some factors associated with survival, such as stage of disease,...
7.
van der Ploeg P, Uittenboogaard A, Thijs A, Westgeest H, Boere I, Lambrechts S, et al.
Gynecol Oncol
. 2021 Jul;
163(2):433-444.
PMID: 34253390
Objective: To determine the clinical benefit of monotherapy with PI3K/AKT/mTOR inhibitors in patients diagnosed with advanced or recurrent ovarian cancer and to investigate the predictive value of current PI3K/AKT/mTOR biomarkers...
8.
van der Ploeg P, van Lieshout L, van de Stolpe A, Bosch S, Lentjes-Beer M, Bekkers R, et al.
Cell Oncol (Dordr)
. 2021 Mar;
44(4):951-957.
PMID: 33723801
Purpose: Anti-estrogen therapy may be used as a palliative treatment option in high-grade serous ovarian carcinomas (HGSC). However, clinical implementation is limited as the use of estrogen receptor (ER) protein...
9.
van Lieshout L, van de Stolpe A, van der Ploeg P, Bowtell D, de Hullu J, Piek J
Cancers (Basel)
. 2020 Sep;
12(9).
PMID: 32961868
We investigated signal transduction pathway (STP) activity in high-grade serous ovarian carcinoma (HGSC) in relation to progression-free survival (PFS) and overall survival (OS). We made use of signal transduction pathway...